ArticleFrontiers in immunology2026
Neutrophil count and platelet-lymphocyte ratio as simple predictors of ustekinumab response in patients with Crohn's disease: a retrospective multicenter study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although ustekinumab (UST) has been recommended by guidelines as a parallel first-line biologic agent for Crohn's disease (CD), its efficacy varies among individuals. This study aimed to identify baseline clinical features and laboratory indicators that can predict clinical remission with UST to assist clinical decision-making. Methods: This retrospective study collected data from patients with CD who received UST induction and maintenance therapy across multiple centers. The primary endpoint was the rate of clinical remission at week 48. Independent predictors of clinical remission were identified by multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves and the Youden index were used to determine optimal cutoff values. Results: Among the 157 included patients, clinical and endoscopic remission rates were 76.4% (120/157) and 51.6% (81/157), respectively. Multivariate analysis showed that baseline neutrophil count and baseline platelet-lymphocyte ratio (PLR) were independent predictors of clinical remission at week 48 with UST treatment. Area under the ROC curve values for baseline neutrophil count, baseline PLR, and their combination were 0.633, 0.709, and 0.769, respectively. Optimal cutoff values for baseline neutrophil count and baseline PLR were ≤4.135×10 Discussion: Baseline neutrophil count and baseline PLR together constitute a simple and effective predictive model. This model may help identify patients who are more responsive to UST before treatment, offering a practical tool for individualized and precise treatment of CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.